Inflammatory disorder

Gilead Sciences Expands into Inflammatory Diseases with $1.7 Billion Collaboration with LEO Pharma

3 months ago talkbio0Tagged Asthma, COPD, Eczema, Gilead Sciences, Inflammatory disorder, inhibitors, JPM25, Pharma, STAT6

Gilead Sciences, LEO Pharma, STAT6 inhibitors, inflammatory diseases, eczema, asthma, COPD, biotech deal, JPM25

Gilead and LEO Pharma Collaborate on STAT6 Inflammatory Disease Programmes

3 months ago talkbio0Tagged Dermatology field, Gilead Sciences, Inflammatory disorder, oral formulations, Partnership, Pharma, STAT6

Gilead Sciences, LEO Pharma, STAT6, inflammatory diseases, partnership, oral formulations, dermatology

Biocon Biologics Secures FDA Approval for YESINTEK, a Biosimilar to Stelara

5 months ago talkbio0Tagged Approved, Biocon, Biological Factors, Inflammatory disorder, Stelara biosimilar, United States Food and Drug Administration, ustekinumab, YESINTEK

Biocon Biologics, FDA approval, YESINTEK, Stelara biosimilar, ustekinumab, inflammatory diseases

Upstream Bio Expands IPO to $255 Million, Set to Join Nasdaq Alongside CAMP4

6 months ago talkbio0Tagged allergic diseases, Biotechnology, CAMP4, Inflammatory disorder, IPO, Nasdaq, Upstream Bio

Upstream Bio, IPO, Nasdaq, CAMP4, Biotechnology, Inflammatory Diseases, Allergic Diseases

Merck & Co. Partners with Mestag Therapeutics to Identify Novel Targets for Inflammatory Diseases

7 months ago talkbio0Tagged Co., Collaboration, Fibroblast-immune interactions, Inflammatory disorder, Mestag, Raft, targets

Mestag Therapeutics, Merck & Co., Inflammatory diseases, Fibroblast-immune interactions, RAFT platform, Therapeutic targets, Collaboration agreement

Merck & Co. and Mestag Therapeutics Collaborate on $1.9 Billion Fibroblast Therapy Deal for Inflammatory Diseases

7 months ago talkbio0Tagged Co., Drug Delivery Systems, Drug/, Fibroblast therapies, Identification (Psychology), Inflammatory disorder, Raft

Merck & Co., Mestag Therapeutics, Fibroblast therapies, Inflammatory diseases, $1.9 billion deal, RAFT platform, Drug target identification

Ventyx Discontinues TYK2 Inhibitor Programme Following Second Mid-Stage Setback

9 months ago talkbio0Tagged Arthritis, Psoriatic, Biosciences, Crohn 's disease, Drug Development, Inflammatory disorder, Inhibitor, Phase 2 Failure, Psoriasis, TYK2 gene, Ventyx, VTX958

Ventyx Biosciences, TYK2 inhibitor, VTX958, Phase 2 failure, psoriasis, psoriatic arthritis, Crohn’s disease, inflammatory diseases, drug development.

AbbVie Acquires Celsius Therapeutics for $250 Million, Expanding Inflammatory Disease Portfolio

10 months ago talkbio0Tagged AbbVie, Acquisition (action), biotech, degrees Celsius, Inflammatory disorder, M&A

AbbVie, Celsius Therapeutics, Acquisition, Inflammatory Diseases, M&A, Biotech

Johnson & Johnson Expands into IL-13 and TSLP Market with Strategic Acquisition

11 months ago talkbio0Tagged Acquisition (action), Biological Factors, competition, Drug Industry, expansion, I&I, Inflammatory disorder, Interleukin-13, Johnson and Johnson, Market, strategic, TSLP gene

Johnson & Johnson, I&I acquisition, IL-13, TSLP, competitive market, strategic expansion, pharmaceutical industry, biologics, inflammatory diseases.

Ajax Pharmaceuticals Secures $95 Million for JAK Inhibitor Drug Development

12 months ago talkbio0Tagged Autoimmune Diseases, Drug Development, Inflammatory disorder, inhibitors, Investments, Janus kinase

Ajax Pharmaceuticals, JAK inhibitors, drug development, funding, investment, inflammatory diseases, autoimmune disorders, cancer.